Posted by Michael Wonder on 02 May 2026
Stelara paediatric Crohn’s disease FDA approval J&J statement
1 May 2026 - On 15 April 2026, the US FDA approved Stelara (ustekinumab) for the treatment of patients two years and older with moderately to severely active Crohn’s disease.
Stelara (ustekinumab) is the only FDA-approved IL-12/23 antagonist and the first non-TNF biologic to treat adult and paediatric patients two years and older with moderately to severely active Crohn’s disease.
